Free Trial

Ontrak (OTRK) Competitors

Ontrak logo
$0.56 -0.02 (-2.95%)
As of 02:12 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

OTRK vs. BGLC, MGRX, SSY, VSEE, DHAC, ATIP, ACON, NIVF, BACK, and BTTX

Should you be buying Ontrak stock or one of its competitors? The main competitors of Ontrak include BioNexus Gene Lab (BGLC), Mangoceuticals (MGRX), SunLink Health Systems (SSY), VSee Health (VSEE), Digital Health Acquisition (DHAC), ATI Physical Therapy (ATIP), Aclarion (ACON), NewGenIvf Group (NIVF), IMAC (BACK), and Better Therapeutics (BTTX). These companies are all part of the "healthcare" industry.

Ontrak vs. Its Competitors

BioNexus Gene Lab (NASDAQ:BGLC) and Ontrak (NASDAQ:OTRK) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, analyst recommendations, earnings, valuation, institutional ownership, dividends, media sentiment and profitability.

BioNexus Gene Lab has a net margin of -22.85% compared to Ontrak's net margin of -274.20%. BioNexus Gene Lab's return on equity of -24.18% beat Ontrak's return on equity.

Company Net Margins Return on Equity Return on Assets
BioNexus Gene Lab-22.85% -24.18% -20.14%
Ontrak -274.20%-269.88%-128.35%

BioNexus Gene Lab has higher earnings, but lower revenue than Ontrak.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BioNexus Gene Lab$9.51M0.92-$1.60MN/AN/A
Ontrak$10.85M0.22-$25.49M-$15.81-0.04

BioNexus Gene Lab has a beta of 5.08, indicating that its share price is 408% more volatile than the S&P 500. Comparatively, Ontrak has a beta of 2.16, indicating that its share price is 116% more volatile than the S&P 500.

Ontrak has a consensus price target of $24.00, indicating a potential upside of 4,132.80%. Given Ontrak's stronger consensus rating and higher possible upside, analysts clearly believe Ontrak is more favorable than BioNexus Gene Lab.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
BioNexus Gene Lab
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Ontrak
0 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
3.00

In the previous week, BioNexus Gene Lab and BioNexus Gene Lab both had 1 articles in the media. Ontrak's average media sentiment score of 1.89 beat BioNexus Gene Lab's score of 1.87 indicating that Ontrak is being referred to more favorably in the news media.

Company Overall Sentiment
BioNexus Gene Lab Very Positive
Ontrak Very Positive

18.9% of BioNexus Gene Lab shares are held by institutional investors. Comparatively, 13.0% of Ontrak shares are held by institutional investors. 0.7% of BioNexus Gene Lab shares are held by insiders. Comparatively, 1.9% of Ontrak shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

BioNexus Gene Lab beats Ontrak on 7 of the 13 factors compared between the two stocks.

Get Ontrak News Delivered to You Automatically

Sign up to receive the latest news and ratings for OTRK and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding OTRK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

OTRK vs. The Competition

MetricOntrakMED IndustryMedical SectorNASDAQ Exchange
Market Cap$2.36M$3.78B$5.71B$9.51B
Dividend YieldN/A1.33%4.60%3.99%
P/E Ratio-0.0432.7028.0720.02
Price / Sales0.22126.47459.47103.02
Price / CashN/A22.4036.5558.97
Price / Book0.244.388.615.88
Net Income-$25.49M$189.47M$3.24B$258.50M
7 Day Performance1.25%1.74%3.83%2.03%
1 Month Performance-42.08%-3.74%10.40%12.52%
1 Year Performance-84.94%-2.86%34.13%19.07%

Ontrak Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
OTRK
Ontrak
3.1368 of 5 stars
$0.57
-3.0%
$24.00
+4,147.8%
-85.2%$2.38M$10.85M-0.04250Positive News
BGLC
BioNexus Gene Lab
1.2027 of 5 stars
$4.94
-3.1%
N/A-4.1%$8.89M$9.51M0.0030Gap Down
MGRX
Mangoceuticals
1.0601 of 5 stars
$1.72
+3.6%
N/A-98.1%$8.89M$620K-0.373Gap Up
SSY
SunLink Health Systems
2.5911 of 5 stars
$1.24
+6.9%
N/A+55.2%$8.73M$31.09M8.861,376News Coverage
Dividend Announcement
Gap Up
High Trading Volume
VSEE
VSee Health
1.1594 of 5 stars
$1.37
+1.5%
$5.00
+265.0%
-56.1%$4.93MN/A0.00N/AGap Up
DHAC
Digital Health Acquisition
N/A$1.35
-3.6%
N/A-62.8%$4.87MN/A0.002,021Gap Down
ATIP
ATI Physical Therapy
N/A$1.03
flat
N/A-94.2%$4.54M$741.86M-0.065,600
ACON
Aclarion
2.9836 of 5 stars
$7.32
+2.8%
$11,758.50
+160,535.2%
-99.7%$4.25M$50K0.007
NIVF
NewGenIvf Group
N/A$0.54
-5.1%
N/A-99.7%$2.33M$5.43M0.00N/ANegative News
Gap Up
BACK
IMAC
N/A$0.06
-35.0%
N/A-96.7%$125K$72.05K0.00180Gap Down
BTTX
Better Therapeutics
N/AN/AN/A-66.7%$5KN/A0.0040

Related Companies and Tools


This page (NASDAQ:OTRK) was last updated on 7/25/2025 by MarketBeat.com Staff
From Our Partners